GlassScriptPhysician profile
Krisczar J Bungay
NPI 1942277660
$554,184.55
in general payments reported to CMS, 2019-2025
66 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $27K · 2021: $32K · 2022: $105K · 2023: $112K · 2024: $96K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $234K · Food and Beverage: $25K · Consulting Fee: $17K · Travel and Lodging: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $234,006.88 |
| Food and Beverage | $25,020.07 |
| Consulting Fee | $16,685.00 |
| Travel and Lodging | $13,356.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $239,171.04 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $218,137.23 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Janssen Products, LP | $34,495.89 | 2019-2023 | Symtuza |
| Idorsia Pharmaceuticals US INC | $17,809.08 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $12,776.63 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $4,416.37 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $4,337.68 | 2019-2024 | |
| Eisai INC. | $3,501.44 | 2019-2022 | |
| Lilly USA, LLC | $1,297.10 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Shionogi INC | $1,245.00 | 2025 | S-217622 |
| Novo Nordisk INC | $1,229.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,221.28 | 2021 | |
| Janssen Biotech, INC. | $1,174.51 | 2019-2023 | Symtuza |
| Axsome Therapeutics, INC. | $1,045.42 | 2023-2025 | Auvelity, Symbravo |
| Astrazeneca Pharmaceuticals LP | $1,020.10 | 2019-2024 | Breztri, Airsupra |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krisczar Bungay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.